Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKT-DC manufacturing from surgical and EBUS-derived lymph nodes in NSCLC
NL-OMON51383Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of activated killer T cells and dendritic cells in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoints: Feasibility of protocol transfer, Optimization of AKT-DC generation from cytology specimens and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
activated killer T cells and dendritic cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51383.